Ra Pharmaceuticals Inc. (RARX)

46.63
NASDAQ : Health Technology
Prev Close 46.71
Day Low/High 46.61 / 46.78
52 Wk Low/High 13.73 / 47.35
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 47.14M
Market Cap 2.20B
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

STOCKHOLDER ALERT: Monteverde & Associates PC Is Investigating The Following Merger

STOCKHOLDER ALERT: Monteverde & Associates PC Is Investigating The Following Merger

NEW YORK, Oct. 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Dova Pharmaceuticals, Inc (...

Here Are Several Promising Rare Disease Stocks

Here Are Several Promising Rare Disease Stocks

These small biotech concerns are undervalued.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Ra Pharmaceuticals, Inc.

NEW YORK, Oct. 10, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Ra Pharmaceuticals, Inc.

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.

Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale Of Ra Pharmaceuticals; Is $48 A Fair Price?

Ra Pharma (RARX) Alert: Johnson Fistel Investigates Proposed Sale Of Ra Pharmaceuticals; Is $48 A Fair Price?

SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Ra Pharmaceuticals, Inc.

UCB Agrees To Acquire Ra Pharmaceuticals: Joining Forces To Improve Treatment Options For People Living With Myasthenia Gravis And Other Rare Diseases

UCB Agrees To Acquire Ra Pharmaceuticals: Joining Forces To Improve Treatment Options For People Living With Myasthenia Gravis And Other Rare Diseases

- Will enhance UCB's leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB's rozanolixizumab, an FcRn targeting antibody also in phase 3

UCB Agrees To Acquire Ra Pharmaceuticals: Joining Forces To Improve Treatment Options For People Living With Myasthenia Gravis And Other Rare Diseases

UCB Agrees To Acquire Ra Pharmaceuticals: Joining Forces To Improve Treatment Options For People Living With Myasthenia Gravis And Other Rare Diseases

regulated information - inside information - UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma.

Ra Pharmaceuticals Announces Dosing Of First Patient In Global Phase 3 Pivotal Study Of Zilucoplan For GMG

Ra Pharmaceuticals Announces Dosing Of First Patient In Global Phase 3 Pivotal Study Of Zilucoplan For GMG

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the initiation of dosing in the RAISE study, its global, pivotal, Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG).

Ra Pharmaceuticals Announces Selection For The First ALS Platform Trial By The Sean M. Healey & AMG Center For ALS At Mass General

Ra Pharmaceuticals Announces Selection For The First ALS Platform Trial By The Sean M. Healey & AMG Center For ALS At Mass General

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the selection of zilucoplan as one of the first clinical candidates to be evaluated in a pioneering platform trial for amyotrophic lateral sclerosis (ALS), led by the Sean M.

Ra Pharmaceuticals Receives Orphan Drug Designation From The U.S. FDA For Zilucoplan For The Treatment Of Myasthenia Gravis

Ra Pharmaceuticals Receives Orphan Drug Designation From The U.S. FDA For Zilucoplan For The Treatment Of Myasthenia Gravis

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that the U.

Ra Pharmaceuticals Earns Clinical Development Milestone For Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement With Merck

Ra Pharmaceuticals Earns Clinical Development Milestone For Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement With Merck

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that it has earned a clinical development milestone under its collaboration agreement with Merck, known as MSD outside the U.

Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results And Provides Corporate Update

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the second quarter ended June 30, 2019, and provided an update on recent corporate and clinical developments.

Ra Pharmaceuticals Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Ra Pharmaceuticals Announces Closing Of Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) ("Ra Pharma") today announced the closing of an underwritten public offering of 4,600,000 shares of its common stock, at a public offering price of $32.

Ra Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Ra Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) ("Ra Pharma") today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, at a public offering price of $32.

Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) ("Ra Pharma") today announced that it intends to offer and sell, subject to market and other conditions, $100 million of its common stock in an underwritten public offering.

Figure 1: Inhibition Of Ex-vivo Sheep Red Blood Cell Hemolysis Assay Following A Single Subcutaneous Dose Of FC XR Formulation Of Zilucoplan In Cynomolgus Monkeys (mean Sem, N=4). (Graphic: Business Wire)

Figure 1: Inhibition Of Ex-vivo Sheep Red Blood Cell Hemolysis Assay Following A Single Subcutaneous Dose Of FC XR Formulation Of Zilucoplan In Cynomolgus Monkeys (mean Sem, N=4). (Graphic: Business Wire)

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) and Camurus AB (Nasdaq STO:CAMX) today announced an exclusive worldwide license agreement for the use of Camurus's proprietary FluidCrystal® (FC) technology to develop, manufacture, and commercialize a long-acting...

Interesting RARX Put And Call Options For August 16th

Interesting RARX Put And Call Options For August 16th

Investors in Ra Pharmaceuticals Inc saw new options begin trading this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RARX options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Ra Pharmaceuticals To Present At Upcoming Investor Conferences

Ra Pharmaceuticals To Present At Upcoming Investor Conferences

Ra Pharmaceuticals, Inc. (Nasdaq: RARX) today announced that senior management will present at the following upcoming investor conferences: The Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019, at 2:30 p.

Ra Pharmaceuticals To Present At Upcoming Investor Conferences

Ra Pharmaceuticals To Present At Upcoming Investor Conferences

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that senior management will present at the following upcoming investor conferences: The UBS Global Healthcare Conference 2019 on Tuesday, May 21, 2019 at 9:00 a.

Ra Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Corporate Update

Ra Pharmaceuticals Reports First Quarter 2019 Financial Results And Provides Corporate Update

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the first quarter ended March 31, 2019, and provided an update on recent corporate and clinical developments.

Ra Pharmaceuticals Announces Positive GMG Phase 2 And Open-Label, Long-Term Extension Data At The 2019 AAN Annual Meeting

Ra Pharmaceuticals Announces Positive GMG Phase 2 And Open-Label, Long-Term Extension Data At The 2019 AAN Annual Meeting

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the presentation of data from the Company's Phase 2 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG), including data from the open-label, long-term...

Ra Pharmaceuticals Presents Pre-Clinical Data For Zilucoplan XR At The 6th Annual Peptides Congress

Ra Pharmaceuticals Presents Pre-Clinical Data For Zilucoplan XR At The 6th Annual Peptides Congress

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6 th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.

Ra Pharmaceuticals Announces Completion Of End-of-Phase 2 Interactions With FDA And Design Of Pivotal Phase 3 GMG Study

Ra Pharmaceuticals Announces Completion Of End-of-Phase 2 Interactions With FDA And Design Of Pivotal Phase 3 GMG Study

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced the successful completion of End-of-Phase 2 interactions with the U.

Ra Pharmaceuticals Announces Acceptance Of GMG Phase 2 And Open-Label, Long-Term Extension Data For Emerging Science Dual Presentation At The 2019 AAN Annual Meeting

Ra Pharmaceuticals Announces Acceptance Of GMG Phase 2 And Open-Label, Long-Term Extension Data For Emerging Science Dual Presentation At The 2019 AAN Annual Meeting

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis (gMG) have been selected for an Emerging Science dual oral and poster presentation at the...

Ra Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Ra Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results And Provides Corporate Update

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2018, and provided an update on recent corporate and clinical developments.